An observational study in Breast Sarcoma, sponsored by Italian Sarcoma Group. Recruiting at 14 sites in Italy. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Italian Sarcoma Group · Observational
This is multi-institutional retrospective study in order to identify the most relevant clinical characteristics, treatment strategies, to explore the impact on principal clinical outcomes and finally, to suggest some principles for management and treatment of breast sarcomas.
The study will collect data about patients affected by breast sarcoma referred to participating Institutions between January 2000 and June 2020
In the field of soft tissue sarcomas, breast sarcomas are a truly peculiar family of rare tumors for both their clinical history and biology of disease.
Surgery (if feasible) is the main therapeutic approach for all the patients with localized disease, while a pharmacological (chemotherapeutic) and/or radiotherapeutic treatment is reserved to those with high-risk/recurrent-relapsing/metastatic disease.
Unfortunately, there is a lack of specific prospective trials in breast sarcoma to guide the clinical decision-making and breast sarcoma patients are often sent to sarcoma referral centers only after surgery Due to sarcoma-specific clinical features, it is clear that both diagnostic and clinical strategies mandate a different approach compared to epithelial tumors. This is of key importance to reach the correct diagnosis, design the best therapeutic decision-making and subsequent follow-up.
Even if retrospective data limitations and biases, in the lack of prospective data collection, these data may be a unique and precious source of information For this reasons this multi-institutional retrospective study is aimed to identify the most relevant clinical characteristics, treatment strategies, to explore the impact on principal clinical outcomes and finally, to suggest some principles for management and treatment of breast sarcomas.
Italian Sarcoma Group is the lead sponsor of 31 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients affected by breast sarcma referred to participating Institutions between January 2000 and June 2020.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort include patients affected by breast sarcoma, referred to participating Institutions between January 2000 and June 2020.
Other: Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)
This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments Reorder Outcome Measures
Treatments received for breast sarcoma
To describe treatment that patient diagnosed with breast sarcoma, received
Time frame: At diagnosis (baseline) and after 6, 12, 18, 24, 36, 48 and 60 weeks
Number of patients with primary breast sarcoma
Number of patient with a diagnosis of primary breast sarcoma
Time frame: Through study inclusion period, an average of 20 years
Number of patients with primary breast sarcoma symptoms
Number of patients with primary breast sarcoma symptoms
Time frame: Through study inclusion period, an average of 20 years
Local-regional Relapse Free Survival (LRFS)
Time elapsed form the treatment (any) start and the onset of Local-regional relapse
Time frame: Every 3 months (Month 3, Month 6, Month 9...) up to 5 years
Progression Free Survival (PFS)
Time elapsed form the treatment (any) start and the onset of progression
Time frame: Every 3 months (Month 3, Month 6, Month 9...) up to 5 years
Overall Survival (OS)
Time elapsed for the diagnosis to the death for any cause
Time frame: at 5 years
Median time of secondary breast sarcoma presentation
To define the median time to secondary sarcoma presentation
Time frame: Up to 3 years
Impact of upfront multidisciplinary tumor board consultation
To describe the impact of upfront multidisciplinary tumor board consultation on outcomes
Time frame: Up to 3 years
Plan to share: No — Not planned
Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Italian Sarcoma Group